Sponsored by
I posted this to show that even though we sometimes feel that no progress is being made, we need to remember how bad this disease is and appreciate what we do have. This report shows that the average survival in this hospital in Saudia Arabia (from 2005 to 2015) is only 8 months! They probably picked 2005 because that is when Temozolomide was approved for Glioblastoma, although it was commonly used here in the USA for Glioblastomas since 1999 when it was approved for anaplastic astrocytoma. (My dad used it for a gbm in 1999!). They do not mention Optune, even though it was approved in 2011.